Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis
Clinical trial NCT01345929 · COMPLETED
Trial details
- NCT number
- NCT01345929
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-06-20
- Primary completion
- 2013-08-11
- Enrollment
- 558
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.